CTLA4 and cancer: Immune checkpoint inhibitors (ICIs), such as programmed death-1/ligand 1 (PD-1/L1) inhibitors and cytotoxic T-lymphocyte-associated protein-4 (CTLA-4) inhibitors, are promising drugs that can enhance the immune system for cancer treatment (1).